BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vadillo C, Nieto MA, Romero-bueno F, Leon L, Sanchez-pernaute O, Rodriguez-nieto MJ, Freites D, Jover JA, Álvarez-sala JL, Abasolo L. Efficacy of rituximab in slowing down progression of rheumatoid arthritis–related interstitial lung disease: data from the NEREA Registry. Rheumatology 2020;59:2099-108. [DOI: 10.1093/rheumatology/kez673] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Li L. Rituximab for connective tissue disease‐associated interstitial lung disease: A systematic review and meta‐analysis. Int J of Rheum Dis 2022. [DOI: 10.1111/1756-185x.14495] [Reference Citation Analysis]
2 Klemm P, Henes J, Xanthouli P. Interstitielle Lungenbeteiligung bei der rheumatoiden Arthritis. Arthritis und Rheuma 2022;42:324-329. [DOI: 10.1055/a-1893-4857] [Reference Citation Analysis]
3 Narváez J, Díaz del Campo Fontecha P, Brito García N, Bonilla G, Aburto M, Castellví I, Cano-jiménez E, Mena-vázquez N, Nieto MA, Ortiz AM, Valenzuela C, Abad Hernández MÁ, Castrejón I, Correyero Plaza M, Francisco Hernández FM, Hernández Hernández MV, Rodríquez Portal JA. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment. Reumatología Clínica (English Edition) 2022. [DOI: 10.1016/j.reumae.2022.03.004] [Reference Citation Analysis]
4 Liossis SC, Bounia CA. Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion. Front Med 2022;9:937561. [DOI: 10.3389/fmed.2022.937561] [Reference Citation Analysis]
5 Diesler R, Cottin V. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies. Expert Rev Respir Med 2022. [PMID: 35695895 DOI: 10.1080/17476348.2022.2089116] [Reference Citation Analysis]
6 Narváez J, Díaz del Campo Fontecha P, Brito García N, Bonilla G, Aburto M, Castellví I, Cano-jiménez E, Mena-vázquez N, Nieto MA, Ortiz AM, Valenzuela C, Abad Hernández MÁ, Castrejón I, Correyero Plaza M, Francisco Hernández FM, Hernández Hernández MV, Rodríquez Portal JA. Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamiento. Reumatología Clínica 2022. [DOI: 10.1016/j.reuma.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chen N, Diao C, Gao J, Zhao D. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: clinical features, biomarkers, and treatment options. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.152004] [Reference Citation Analysis]
8 Yu KH, Chen HH, Cheng TT, Jan YJ, Weng MY, Lin YJ, Chen HA, Cheng JT, Huang KY, Li KJ, Su YJ, Leong PY, Tsai WC, Lan JL, Chen DY. Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine (Baltimore) 2022;101:e28501. [PMID: 35029907 DOI: 10.1097/MD.0000000000028501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 van den Bosch L, Luppi F, Ferrara G, Mura M. Immunomodulatory treatment of interstitial lung disease. Ther Adv Respir Dis 2022;16:17534666221117002. [PMID: 35938712 DOI: 10.1177/17534666221117002] [Reference Citation Analysis]
10 Wilfong EM, Aggarwal R. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. Ther Adv Musculoskelet Dis 2021;13:1759720X211060907. [PMID: 34917177 DOI: 10.1177/1759720X211060907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Al Nokhatha SA, Harrington R, Conway R. Le méthotrexate est-il contre-indiqué dans les atteintes pulmonaires de la polyarthrite rhumatoïde ? Revue du Rhumatisme 2021;88:399-401. [DOI: 10.1016/j.rhum.2021.04.010] [Reference Citation Analysis]
12 D'Silva KM, Ventura IB, Bolster MB, Castelino FV, Sharma A, Little BP, Adegunsoye A, Strek ME, Choi H, Montesi SB. Rituximab for interstitial pneumonia with autoimmune features at two medical centres. Rheumatol Adv Pract 2021;5:ii1-9. [PMID: 34755024 DOI: 10.1093/rap/rkab051] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Kelly C, Emery P, Dieudé P. Current issues in rheumatoid arthritis-associated interstitial lung disease. The Lancet Rheumatology 2021;3:e798-e807. [DOI: 10.1016/s2665-9913(21)00250-2] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Lee JS, Kim GJ, Ha YJ, Kang EH, Lee YJ, Goldin JG, Lee EY. The Extent and Diverse Trajectories of Longitudinal Changes in Rheumatoid Arthritis Interstitial Lung Diseases Using Quantitative HRCT Scores. J Clin Med 2021;10:3812. [PMID: 34501260 DOI: 10.3390/jcm10173812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kawano-Dourado L, Lee JS. Management of Connective Tissue Disease-Associated Interstitial Lung Disease. Clin Chest Med 2021;42:295-310. [PMID: 34024405 DOI: 10.1016/j.ccm.2021.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Nieto MA, Rodriguez-Nieto MJ, Sanchez-Pernaute O, Romero-Bueno F, Leon L, Vadillo C, Freites-Nuñez DD, Jover JA, Álvarez-Sala JL, Abasolo L. Mortality rate in rheumatoid arthritis-related interstitial lung disease: the role of radiographic patterns. BMC Pulm Med 2021;21:205. [PMID: 34193085 DOI: 10.1186/s12890-021-01569-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Salvarani C, Sebastiani M, Dieude P, Garcia M, Deberdt W, Rogai V, de la Torre I, Inciarte-Mundo J, Balsa A. Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials. Rheumatol Ther 2021;8:1435-41. [PMID: 34184191 DOI: 10.1007/s40744-021-00332-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
18 Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Castañeda S, González-Gay MÁ. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. Autoimmun Rev 2021;20:102830. [PMID: 33887489 DOI: 10.1016/j.autrev.2021.102830] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
19 Castelino FV, Moua T. Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. ACR Open Rheumatol 2021;3:295-304. [PMID: 33779080 DOI: 10.1002/acr2.11253] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Cronin O, McKnight O, Keir L, Ralston SH, Hirani N, Harris H. A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease. Rheumatol Int 2021;41:921-8. [PMID: 33721094 DOI: 10.1007/s00296-021-04835-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Narváez J, Otón T, Calvo-Alén J, Escudero-Contreras A, Muñoz-Fernández S, Rodríguez-Heredia JM, Romero-Yuste S, Vela-Casasempere P, Luján S, Baquero JL, Carmona L. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey. Joint Bone Spine 2021;88:105172. [PMID: 33689842 DOI: 10.1016/j.jbspin.2021.105172] [Reference Citation Analysis]
22 Kreuter M, Ladner UM, Costabel U, Jonigk D, Heussel CP. The Diagnosis and Treatment of Pulmonary Fibrosis. Dtsch Arztebl Int 2021;118:arztebl. [PMID: 33531115 DOI: 10.3238/arztebl.m2021.0018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Korsten P, Konig MF, Tampe B, Mirsaeidi M. Editorial: Interstitial Lung Disease in the Context of Systemic Disease: Pathophysiology, Treatment and Outcomes. Front Med (Lausanne) 2020;7:644075. [PMID: 33585522 DOI: 10.3389/fmed.2020.644075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Vacchi C, Manfredi A, Cassone G, Erre GL, Salvarani C, Sebastiani M. Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. Drugs Context 2021;10:2020-8-7. [PMID: 33505478 DOI: 10.7573/dic.2020-8-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
25 Conway R, Nikiphorou E. Treating interstitial lung disease in rheumatoid arthritis - the embers of hope. Rheumatology (Oxford) 2020;59:3589-90. [PMID: 33068432 DOI: 10.1093/rheumatology/keaa516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Romano C, Esposito S, Ferrara R, Cuomo G. Tailoring biologic therapy for real-world rheumatoid arthritis patients. Expert Opin Biol Ther 2021;21:661-74. [PMID: 33147106 DOI: 10.1080/14712598.2021.1847268] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Narváez J, Robles-pérez A, Molina-molina M, Vicens-zygmunt V, Luburich P, Yañez MA, Alegre JJ, Nolla JM. Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease. Seminars in Arthritis and Rheumatism 2020;50:902-10. [DOI: 10.1016/j.semarthrit.2020.08.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
28 Atienza-Mateo B, Remuzgo-Martínez S, Prieto-Peña D, Mora Cuesta VM, Iturbe-Fernández D, Llorca J, Sánchez-Bilbao L, Corrales A, Blanco Rodríguez G, Gómez-Román JJ, Cifrián JM, González-Gay MÁ. Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review. J Clin Med 2020;9:E3070. [PMID: 32977717 DOI: 10.3390/jcm9103070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
29 Satış H, Oruç A, Avcu A, Karadeniz H, Güler AA, Kayahan N. Comment on: Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. Rheumatology (Oxford) 2020;59:2180. [PMID: 32442283 DOI: 10.1093/rheumatology/keaa171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]